Literature DB >> 9559818

In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.

P M Roblin1, M R Hammerschlag.   

Abstract

The in vitro susceptibilities of 10 strains of Chlamydia pneumoniae to a new 8-methoxyquinolone, BAY 12-8039, and to ofloxacin, doxycycline, and erythromycin were determined. The activity of BAY 12-8039 was similar to that of ofloxacin, with a MIC at which 90% of the isolates had no inclusions and a minimal chlamydicidal concentration at which 90% of the isolates had no inclusions after passage of 1.0 microg/ml, but this activity was less than those of doxycycline and erythromycin.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9559818      PMCID： PMC105577          DOI： 10.1128/AAC.42.4.951

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae.

Authors:  P M Roblin; W Dumornay; M R Hammerschlag
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

2.  In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR).

Authors:  K Chirgwin; P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  In vitro activity of trovafloxacin against Chlamydia pneumoniae.

Authors:  P M Roblin; A Kutlin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group.

Authors:  J F Plouffe; M T Herbert; T M File; I Baird; J N Parsons; J B Kahn; K T Rielly-Gauvin
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections.

Authors:  B A Lipsky; K J Tack; C C Kuo; S P Wang; J T Grayston
Journal:  Am J Med       Date:  1990-12       Impact factor: 4.965

6.  In vitro activity of BAY 12-8039, a new fluoroquinolone.

Authors:  J M Woodcock; J M Andrews; F J Boswell; N P Brenwald; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

Review 7.  A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

Authors:  J T Grayston; L A Campbell; C C Kuo; C H Mordhorst; P Saikku; D H Thom; S P Wang
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

8.  In vitro activities of five quinolones against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; C L Hyman; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

9.  In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; K K Qumei; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

10.  Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.

Authors:  S Block; J Hedrick; M R Hammerschlag; G H Cassell; J C Craft
Journal:  Pediatr Infect Dis J       Date:  1995-06       Impact factor: 2.129
View more
  9 in total

1.  Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers.

Authors:  J Lettieri; R Vargas; V Agarwal; P Liu
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.

Authors:  P M Roblin; T Reznik; A Kutlin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 3.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Moxifloxacin.

Authors:  J A Balfour; L R Wiseman
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

Review 5.  Activity of quinolones against Chlamydia pneumoniae.

Authors:  M R Hammerschlag
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 6.  Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.

Authors:  J A Balfour; H M Lamb
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

7.  Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.

Authors:  H Portier; C Brambilla; M Garre; F Paganin; P Poubeau; P Zuck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-06       Impact factor: 3.267

8.  In vitro and in vivo activities of sitafloxacin against Chlamydia spp.

Authors:  N Miyashita; Y Niki; T Matsushima
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.

Authors:  Satoshi Ameyama; Yuko Shinmura; Masahiro Takahata
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.